首页 > 期刊杂志 > 正文

Correlation of cytomorphology and molecular findings in EGFR+, KRAS+, and ALK+ lung carcinomas.

EGFR、KRAS和ALK阳性的肺癌中细胞形态和分子特征的相关性

Li Z,Dacic S,Pantanowitz L,Khalbuss WE,Nikiforova MN,Monaco SE

Abstract

There is increasing emphasis on the subclassification of non-small cell lung carcinomas (NSCLCs) and molecular features to guide treatment. Histologic studies have suggested some morphologic features predominating in tumors. Our aim was to determine if mutated cases had distinct cytomorphology.
A retrospective study was designed to retrieve all cytopathology cases of NSCLC that had mutation studies for EGFR or KRAS or fluorescence in situ hybridization studies for ALK between 2007 and 2012. All slides from available mutation-positive cases were reviewed, and cytomorphologic features were correlated to mutation status.
Of the cases with molecular testing, 62 (39%) of 160 were positive for mutation, including 39 (31%) positive for KRAS, 20 (14%) for EGFR, and 4 (3%) for ALK (one case positive for both EGFR and ALK). More of ALK+ and KRAS+ cases had a diagnosis of NSCLC-favor adenocarcinoma or NSCLC not otherwise specified than did EGFR+ cases (25; 51% vs 5%). Eosinophilic granular cytoplasm was seen in more ALK and KRAS cases than in EGFR cases (100; 32% vs 6%).
Cytologic features of ALK+ and KRAS+ tumors included more nuclear pleomorphism, necrosis, and a less vacuolated cytoplasm than did EGFR+ tumors, which may explain the less definitive subclassification in ALK+ and KRAS+ tumors.

摘要

对非小细胞肺癌(NSCLCs)亚型和指导治疗的分子特征关注越来越多。组织学研究表明,部分形态学特征在肿瘤中占主导地位。本文旨在确定突变病例是否存在独特的细胞形态学特征。
回顾性研究2007年-2012年EGFR或KRAS突变、荧光原位杂交检测ALK的所有NSCLC细胞病理学病例。突变检测阳性的所有病例均进行了回顾,并将细胞形态学特征和突变状态联系到一起。
进行分子检测的160例中,62例(39%)突变阳性,包括39例(31%)KRAS阳性,20例(14%)EGFR阳性,4例ALK阳性(1例EGFR和ALK均阳性)。相比EGFR阳性病例来说,ALK阳性和KRAS阳性的病例更多(25;51%vs5%)倾向腺癌或非特殊类型NSCLC的诊断。相比EGFR阳性病例,ALK和KRAS阳性病例更多出现嗜酸性颗粒样胞质(100;32%vs6%)。
相比EGFR阳性的肿瘤来说,ALK和KRAS阳性肿瘤的细胞特征包括核多形性更显着、坏死和少量胞质空泡,这也许可以解释在ALK和KRAS阳性肿瘤中亚型更不确定的问题。

full text

我要评论

0条评论